Patent US20190298785A1, filing in 26 April 2019 (2021)
Anticoagulants such as warfarin, direct oral anticoagulants (DOACs), and injectable agents reduce the ability of blood to clot by interfering with clotting factors in the bloodstream
By slowing digestion and altering gut motility, it creates the fullness and appetite control that make it effective, but those same mechanisms can also trigger nausea, bloating, or discomfort
Injectable hydroxocobalamin is the standard UK treatment for confirmed B12 deficiency, particularly when neurological symptoms are present or absorption is impaired, providing rapid correction with doses given initially three times weekly then every two to three months
Proteins belonging to the FOXO family were identified as key transcription factors involved in cellular stress regulation and longevity-associated signalling pathways
Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations
